This guidance will fully update the following:
 
Status In progress
Process STA Review
ID number 1012

Provisional Schedule

Final appraisal determination 10 August 2017 - 24 August 2017

Project Team

Project lead Jenna Dilkes

Email enquiries

Consultees

Companies sponsors Bayer
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups British Liver Trust
Professional groups British Association for the Study of the Liver
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies • Bayer (doxorubicin) (Confidentiality agreement not signed, not participating)
  • Teva UK (doxorubicin) (Confidentiality agreement not signed, not participating)
  • Eli Lilly & Company (gemcitabine) (Confidentiality agreement not signed, not participating)
  • Hospira UK (mitoxantrone, doxorubicin, generic fluorouracil, cisplatin, oxaliplatin) (Confidentiality agreement not signed, not participating)
  • Medac UK (fluorouracil) (Confidentiality agreement not signed, not participating)
  • Pfizer (doxorubicin, cisplatin) (Confidentiality agreement not signed, not participating)
  • Roche Products (capecitabine, bevacizumab) (Confidentiality agreement not signed, not participating)
  • Sanofi (oxaliplatin) (Confidentiality agreement not signed, not participating)
  • Wockhardt UK (mitoxantrone, doxorubicin, fluorouracil, cisplatin) (Confidentiality agreement not signed, not participating)
General commentators Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
01 February 2017 Committee meeting: 3
21 December 2016 - 23 January 2017 Appraisal consultation: 2
29 November 2016 Committee meeting: 2
12 August 2016 - 12 September 2016 Appraisal consultation: 1
26 July 2016 Committee meeting

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance